National and Kapodistrian University of Athens
Σύγκριση μοριακά στοχευμένων θεραπειών πρώτης γραμμής στο μεταστατικό καρκίνωμα του νεφρού: μετα-ανάλυση
Abstract
dc:descriptionBetter understanding of renal cell carcinogenesis has led to the development of molecular therapies targeting the VEGF and mTOR pathways, as well as immunotherapeutic agents (ICPIs) up-regulating the host immune response, resulting in significant improvement in overall survival and quality of life in patients with metastatic clear cell renal cell carcinoma (mccRCC).Objective. Direct and indirect comparison of targeted agents used in first-line treatment in mccRCC.Methods. A systematic literature review was conducted in order to identify randomized controlled studies (RCS) in the first-line therapy for mRCC. The outcomes analysed were overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and some adverse events (AEs). A network meta-analysis was conducted comparing OS and PFS Hazard Ratios (HRs) and ORR and AEs Odds Ratios (ORs).Results. Treatment’s efficacy: Nivolumab/Ipilimumab (NIV/IPI) and sorafenib (SOR), compared to placebo, prolonged OS (HRs 0.63 and 0.77, respectively). Axitinib (AXI), cabozantinib (CAB), temsirolimus (TEM), pazopanib (PAZ), TEM/IFN and tivozanib (TIV) also prolonged OS, but not significantly (HRs 0.77, 0.80, 0.89, 0.91, 0.93 and 0.96, respectively). CAB, sunitinib (SUN), AXI, TIV, PAZ, SOR and EVE demonstrated significant superiority in terms of PFS (HRs 0.17, 0.36, 0.37, 0.39, 0.41, 0.48 and 0.50, respectively). As for ORR, CAB, NIV/IPI, AXI, PAZ, BEV/IFNα, SUN, TIV and SOR presented significant improvement, compared to placebo (ORs 27.99, 20.72, 16.39, 14.95, 11.87, 10.54, 9.75 and 6.01, respectively). Treatment’s safety: TEM, EVE, BEV and NIV/IPI have had the best profile of AEs G 3/4 (OR 1.88, 1.99, 2.14 and 2.64, respectively). AEs leading to discontinuation of therapy were lower in TIV, TEM and SOR (ORs 0.52, 1.17 and 1.27, respectively). Hypertension events occurred mostly with AXI, CAB, TIV, PAZ, SUN and SOR (OR 63.30, 10.94, 6.96, 7.06, 7.07 and 4.45, respectively). HFS developed in PAZ, SOR, CAB SUN and AXI (OR 152.89, 58.23, 55.59, 26.33 and 22.33, respectively) and diarrhea mostly in AXI and SOR (OR 7.59 and 4.29, respectively).Conclusions. According to the results of this meta-analysis, NIV/IPI and CAB are indicated, with cautiousness, for front-line therapy in intermediate and high risk patients with mccRCC. AXI (with cautiousness) , PAZ, SUN, SOR, BEV/IFN and TIV are mainly preferred as first-line therapy in favorable and intermediate risk patients with mccRCC.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tegos, Theodoros
- Τέγος, Θεόδωρος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46080